GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006979 | Colorectum | AD | response to oxidative stress | 145/3918 | 446/18723 | 5.16e-09 | 3.23e-07 | 145 |
GO:0016049 | Colorectum | AD | cell growth | 143/3918 | 482/18723 | 2.83e-06 | 8.09e-05 | 143 |
GO:0001558 | Colorectum | AD | regulation of cell growth | 124/3918 | 414/18723 | 7.67e-06 | 1.86e-04 | 124 |
GO:0018105 | Colorectum | AD | peptidyl-serine phosphorylation | 88/3918 | 315/18723 | 1.73e-03 | 1.43e-02 | 88 |
GO:0018209 | Colorectum | AD | peptidyl-serine modification | 92/3918 | 338/18723 | 3.19e-03 | 2.36e-02 | 92 |
GO:0032411 | Colorectum | AD | positive regulation of transporter activity | 37/3918 | 120/18723 | 6.82e-03 | 4.22e-02 | 37 |
GO:00069791 | Colorectum | SER | response to oxidative stress | 114/2897 | 446/18723 | 1.75e-08 | 1.28e-06 | 114 |
GO:00015581 | Colorectum | SER | regulation of cell growth | 90/2897 | 414/18723 | 4.00e-04 | 6.02e-03 | 90 |
GO:00160491 | Colorectum | SER | cell growth | 100/2897 | 482/18723 | 1.07e-03 | 1.24e-02 | 100 |
GO:00324111 | Colorectum | SER | positive regulation of transporter activity | 31/2897 | 120/18723 | 2.25e-03 | 2.16e-02 | 31 |
GO:00181051 | Colorectum | SER | peptidyl-serine phosphorylation | 66/2897 | 315/18723 | 5.47e-03 | 4.06e-02 | 66 |
GO:0032409 | Colorectum | SER | regulation of transporter activity | 65/2897 | 310/18723 | 5.71e-03 | 4.19e-02 | 65 |
GO:00160493 | Colorectum | FAP | cell growth | 112/2622 | 482/18723 | 2.40e-08 | 2.30e-06 | 112 |
GO:00069794 | Colorectum | FAP | response to oxidative stress | 102/2622 | 446/18723 | 2.29e-07 | 1.33e-05 | 102 |
GO:00015583 | Colorectum | FAP | regulation of cell growth | 95/2622 | 414/18723 | 5.02e-07 | 2.61e-05 | 95 |
GO:00181053 | Colorectum | FAP | peptidyl-serine phosphorylation | 71/2622 | 315/18723 | 2.51e-05 | 5.82e-04 | 71 |
GO:00182092 | Colorectum | FAP | peptidyl-serine modification | 73/2622 | 338/18723 | 8.47e-05 | 1.51e-03 | 73 |
GO:00324092 | Colorectum | FAP | regulation of transporter activity | 67/2622 | 310/18723 | 1.59e-04 | 2.43e-03 | 67 |
GO:00324113 | Colorectum | FAP | positive regulation of transporter activity | 29/2622 | 120/18723 | 1.97e-03 | 1.65e-02 | 29 |
GO:00181055 | Liver | NAFLD | peptidyl-serine phosphorylation | 63/1882 | 315/18723 | 7.45e-08 | 6.60e-06 | 63 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SGK2 | SNV | Missense_Mutation | | c.187N>C | p.Ser63Pro | p.S63P | Q9HBY8 | protein_coding | deleterious(0.03) | benign(0.097) | TCGA-AQ-A04H-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
SGK2 | SNV | Missense_Mutation | | c.116N>T | p.Pro39Leu | p.P39L | Q9HBY8 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SGK2 | SNV | Missense_Mutation | novel | c.982N>T | p.Leu328Phe | p.L328F | Q9HBY8 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SGK2 | SNV | Missense_Mutation | novel | c.629N>C | p.Leu210Pro | p.L210P | Q9HBY8 | protein_coding | deleterious(0.01) | possibly_damaging(0.867) | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
SGK2 | SNV | Missense_Mutation | rs778281277 | c.188C>G | p.Ser63Cys | p.S63C | Q9HBY8 | protein_coding | deleterious(0.04) | benign(0.334) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SGK2 | SNV | Missense_Mutation | | c.99N>A | p.Met33Ile | p.M33I | Q9HBY8 | protein_coding | tolerated_low_confidence(0.09) | benign(0) | TCGA-D8-A27L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cuclophosphamide | SD |
SGK2 | SNV | Missense_Mutation | rs774838630 | c.943G>A | p.Gly315Arg | p.G315R | Q9HBY8 | protein_coding | tolerated(0.48) | benign(0.051) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
SGK2 | insertion | Nonsense_Mutation | novel | c.631_632insGGCAGGCGGGCAGGTGAAAAAAAAAGAAAAG | p.His211ArgfsTer6 | p.H211Rfs*6 | Q9HBY8 | protein_coding | | | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SGK2 | deletion | Frame_Shift_Del | novel | c.1268delN | p.Asp423AlafsTer34 | p.D423Afs*34 | Q9HBY8 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
SGK2 | SNV | Missense_Mutation | novel | c.446A>C | p.Lys149Thr | p.K149T | Q9HBY8 | protein_coding | deleterious(0.01) | possibly_damaging(0.901) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | | SP-600125 | SP-600125 | |
10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | | DOVITINIB | DOVITINIB | |
10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | | AZD-1080 | AZD-1080 | |
10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | | GW441756X | GW441756X | |
10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 249565720 | | |
10110 | SGK2 | ION CHANNEL, KINASE, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, DRUGGABLE GENOME | | FASUDIL | FASUDIL | |